Addition of epirubicin as a third drug to carboplatin- paclitaxel in first-line treatment of advanced ovarian cancer : A prospectively randomized gynecologic cancer intergroup trial by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group and the groupe d'investigateurs nationaux pour l'etude des cancers ovariensDU BOIS, Andreas; WEBER, Beatrice; RICHTER, Barbara et al.Journal of clinical oncology. 2006, Vol 24, Num 7, pp 1127-1135, issn 0732-183X, 9 p.Article

Pegylated Liposomal Doxorubicin and Carboplatin in Late-relapsing Ovarian Cancer: A GINECO Group Phase II TrialWEBER, Béatrice; LORTHOLARY, Alain; PUJADE-LAURAINE, Eric et al.Anticancer research. 2009, Vol 29, Num 10, pp 4195-4200, issn 0250-7005, 6 p.Article

A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer : results of the ERASME 3 studyCASSIER, Philippe A; CHABAUD, Sylvie; AGOSTINI, Cecile et al.Breast cancer research and treatment. 2008, Vol 109, Num 2, pp 343-350, issn 0167-6806, 8 p.Article

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyFACON, Thierry; MARY, Jean-Yves; HAROUSSEAU, Jean-Luc et al.Blood. 2006, Vol 107, Num 4, pp 1292-1298, issn 0006-4971, 7 p.Article

Identification of a leukemic counterpart of the plasmacytoid dendritic cellsCHAPEROT, Laurence; BENDRISS, Nathalie; BENSA, Jean-Claude et al.Blood. 2001, Vol 97, Num 10, pp 3210-3217, issn 0006-4971Article